RxDoctor Payments Data

Jacklyn Besch

Family · Davenport, IANPI 1982030946

Payments from drug & device makers

$516in general payments, 2019–2025

Across 25 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$102
  • AbbVie$72
  • Exact Sciences$60
  • Pfizer$57
  • Otsuka America Pharmaceutical, Inc.$41
  • Axsome Therapeutics, Inc.$37
  • plus $147 from 7 others

What the payments were for

  • Food & beverage$516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$516 in reported general payments places this provider in the 65th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$2,108
Medicare patients
35
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$106,909
JardianceEmpagliflozin53$68,623
FarxigaDapagliflozin Propanediol42$54,045
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$48,922
JanuviaSitagliptin Phosphate49$42,488
TrulicityDulaglutide41$41,229
MounjaroTirzepatide37$37,704
EliquisApixaban39$28,782
TradjentaLinagliptin26$20,271
WegovySemaglutide14$18,565
JubliaEfinaconazole11$16,444
Breo ElliptaFluticasone/Vilanterol32$15,550
Spiriva HandihalerTiotropium Bromide17$14,595
SymbicortBudesonide/Formoterol Fumarate50$13,619
MyrbetriqMirabegron14$8,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Levemir, Novolog$102$132,624149 claims
Lilly USA, LLCTrulicity, Mounjaro$20$78,93378 claims
PfizerEliquis$57$28,78239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,268 family providers in Iowa.

Other family in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →